Form 6-K Sanofi For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Sanofi-Aventis (SNY) PT Raised to $60 at Argus
July 26, 2024 7:33 AM EDTArgus analyst Jasper Hellweg raised the price target on Sanofi-Aventis (NASDAQ: SNY) to $60.00 (from $55.00) while maintaining a Buy rating.
The analyst comments "Our rating on Sanofi SA (NGS: SNY), a leading global pharmaceutical company, is BUY. We like Sanofis diverse range of businesses, which include branded pharmaceuticals, generics, vaccines, and consumer healthcare products. The... More
